An open-label single-arm, phase II trial of zalutumumab, a human monoclonal anti-EGFR antibody, in patients with platinum-refractory squamous cell carcinoma of the head and neck
作者： Vassiliki Saloura , Ezra E. W. Cohen , Lisa Licitra , Salem Billan , Jose Dinis
DOI: 10.1007/S00280-014-2459-Z
关键词:
摘要: Purpose Treatment options for patients with platinum-refractory recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) are limited. The purpose this study was to assess efficacy safety zalutumumab in R/M SCCHN.
springer.com
elsevier.com
sci-hub.se 参考文章(26)
S. Tejpar, M. Peeters, Y. Humblet, H. Gelderblom, J. Vermorken, F. Viret, B. Glimelius, F. Ciardiello, O. Kisker, E. Van Cutsem, Dose-escalation study using up to twice the standard dose of cetuximab in patients with metastatic colorectal cancer (mCRC) with no or slight skin reactions on cetuximab standard dose treatment (EVEREST study): Preliminary data Journal of Clinical Oncology. ,vol. 24, pp. 3554- 3554 ,(2006) , 10.1200/JCO.2006.24.18_SUPPL.3554
P Camus, S Kudoh, M Ebina, Interstitial lung disease associated with drug therapy British Journal of Cancer. ,vol. 91, ,(2004) , 10.1038/SJ.BJC.6602063
Román Peréz-Soler, Leonard Saltz, Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining? Journal of Clinical Oncology. ,vol. 23, pp. 5235- 5246 ,(2005) , 10.1200/JCO.2005.00.6916
X. León, R. Hitt, M. Constenla, A. Rocca, R. Stupp, A.F. Kovács, N. Amellal, E.H. Bessa, J. Bourhis, A Retrospective Analysis of the Outcome of Patients with Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck Refractory to a Platinum-based Chemotherapy Clinical Oncology. ,vol. 17, pp. 418- 424 ,(2005) , 10.1016/J.CLON.2005.02.014
Qichun Wei, Liming Sheng, Yongjie Shui, Qiongge Hu, Hans Nordgren, Jorgen Carlsson, EGFR, HER2, and HER3 expression in laryngeal primary tumors and corresponding metastases Annals of Surgical Oncology. ,vol. 15, pp. 1193- 1201 ,(2008) , 10.1245/S10434-007-9771-3
Lars Bastholt, Lena Specht, Kenneth Jensen, Eva Brun, Annika Loft, Jørgen Petersen, Helle Kastberg, Jesper G. Eriksen, Phase I/II clinical and pharmacokinetic study evaluating a fully human monoclonal antibody against EGFr (HuMax-EGFr) in patients with advanced squamous cell carcinoma of the head and neck Radiotherapy and Oncology. ,vol. 85, pp. 24- 28 ,(2007) , 10.1016/J.RADONC.2007.06.007
Jennifer Rubin Grandis, Mona F. Melhem, William E. Gooding, Roger Day, Valerie A. Holst, Marilyn M. Wagener, Stephanie D. Drenning, David J. Tweardy, Levels of TGF-α and EGFR Protein in Head and Neck Squamous Cell Carcinoma and Patient Survival Journal of the National Cancer Institute. ,vol. 90, pp. 824- 832 ,(1998) , 10.1093/JNCI/90.11.824
Natalie R. Young, Jing Liu, Carolyn Pierce, Tai-Fen Wei, Tatyana Grushko, Olufunmilayo I. Olopade, Wanqing Liu, Christine Shen, Tanguy Y. Seiwert, Ezra E.W. Cohen, Molecular phenotype predicts sensitivity of squamous cell carcinoma of the head and neck to epidermal growth factor receptor inhibition Molecular Oncology. ,vol. 7, pp. 359- 368 ,(2013) , 10.1016/J.MOLONC.2012.11.001
Marc Peeters, Salvatore Siena, Eric Van Cutsem, Alberto Sobrero, Alain Hendlisz, Stefano Cascinu, Haralabos Kalofonos, Giovanna Devercelli, Michael Wolf, Rafael G. Amado, Association of progression-free survival, overall survival, and patient-reported outcomes by skin toxicity and KRAS status in patients receiving panitumumab monotherapy Cancer. ,vol. 115, pp. 1544- 1554 ,(2009) , 10.1002/CNCR.24088
Vladimir Ratushny, Igor Astsaturov, Barbara A. Burtness, Erica A. Golemis, Joshua S. Silverman, Targeting EGFR resistance networks in head and neck cancer. Cellular Signalling. ,vol. 21, pp. 1255- 1268 ,(2009) , 10.1016/J.CELLSIG.2009.02.021